Temporal trends and predictors for cancer clinical trial availability for medically underserved populations

Oncologist

Volumn 20, Issue 6, 2015, Pages 674-682

  Gerber, David E ^a,b,c   Lakoduk, Ashley M ^a   Priddy, Laurin L ^b   Yan, Jingsheng ^b   Xie, Xian Jin ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

Author keywords

Accrual; Cancer; Clinical trials; Underrepresented minorities; Underserved populations

Indexed keywords

ARTICLE; CANCER RESEARCH; CLINICAL RESEARCH; CLINICAL STUDY; ECONOMIC ASPECT; INTERVENTION STUDY; MANTEL HAENSZEL TEST; PRIORITY JOURNAL; CLINICAL TRIAL (TOPIC); HUMAN; NEOPLASMS; PATHOLOGY; UNITED STATES; VULNERABLE POPULATION;

CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; UNITED STATES; VULNERABLE POPULATIONS;

EID: 84932612073     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0083     Document Type: Article

References (38)

1. Viability of cancer clinical research: Patient accrual, coverage, and reimbursement. American Medical Association Council on Scientific Affairs. J Natl Cancer Inst 1991;83:254–259.
2. Sateren WB, Trimble EL, Abrams J et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. J Clin Oncol 2002;20:2109–2117.
3. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: Race-, sex-, and age-based disparities. JAMA 2004;291:2720–2726.
4. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003;21:1383–1389.
5. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: A 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004;22: 4626–4631.
6. Advani AS, Atkeson B, Brown CLetal. Barriers to the participation of African-American patients with cancer in clinical trials: A pilot study. Cancer 2003; 97:1499-1506.
7. Du W, Gadgeel SM, Simon MS. Predictors of enrollment in lung cancer clinical trials. Cancer 2006;106:420-425.
8. Shavers VL, Lynch CF, Burmeister LF. Factors that influence African-Americans’ willingness to participate in medical research studies. Cancer 2001;91(suppl):233-236.
9. Steinberg ML, Fremont A, Khan DC et al. Lay patient navigator program implementation for equal access to cancer care and clinical trials: Essential steps and initial challenges. Cancer 2006; 107:2669-2677.
10. Howerton MW, Gibbons MC, Baffi CR et al. Provider roles in the recruitment of underrepre-sented populations to cancer clinical trials. Cancer 2007;109:465-476.
11. Fallowfield L, Jenkins V, Farewell V et al. Efficacy of a Cancer Research UK communication skills training model for oncologists: A randomised controlled trial. Lancet 2002;359:650-656.
12. Hietanen PS, Aro AR, Holli KA et al. A short communication course for physicians improves the quality of patient information in a clinical trial. Acta Oncol 2007;46:42-48.
13. Jenkins V, Fallowfield L, Solis-Trapala I et al. Discussing randomised clinical trials of cancer therapy: Evaluation of a Cancer Research UK training programme. BMJ 2005;330:400.
14. Razavi D, Merckaert I, Marchal S et al. How to optimize physicians’ communication skills in cancer care: Results of a randomized study assessing the usefulness of posttrainingconsolidation workshops. J Clin Oncol 2003;21:3141-3149.
15. Rasco DW, Xie Y, Yan J et al. The impact of consenter characteristics and experience on patient interest in clinical research. The Oncologist 2009;14: 468-475.
16. 16. Gerber DE, Rasco DW, Skinner CS et al. Consent timing and experience: Modifiable factors that may influence interest in clinical research. J Oncol Pract 2012;8:91-96.
17. McCusker J, Wax A, Bennett JM. Cancer patient accessions into clinical trials: A pilot investigation into some patient and physician determinants of entry. Am J Clin Oncol 1982;5:227-236.
18. Kotwall CA, Mahoney LJ, Myers RE et al. Reasons for non-entry in randomized clinical trials for breast cancer: A single institutional study. J Surg Oncol 1992;50:125-129.
19. Lee JY, Breaux SR. Accrual of radiotherapy patients to clinical trials. Cancer 1983;52:1014-1016.
20. Simon MS, Du W Flaherty L et al. Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 2004;22:2046-2052.
21. Fuks A, Weijer C, Freedman B et al. A study in contrasts: Eligibility criteria in a twenty-year sample of NSABP and POG clinical trials. National Surgical Adjuvant Breast and Bowel Program. Pediatric Oncology Group. J Clin Epidemiol 1998;51:69-79.
22. Gerber DE, Laccetti AL, Xuan L et al. Impact of prior cancer on eligibility for lung cancer clinical trials. J Natl Cancer Inst 2014;106.
23. Mouton CP, Harris S, Rovi S et al. Barriers to black women’s participation in cancer clinical trials. J Natl Med Assoc 1997;89:721-727.
24. Ellis PM, Butow PN, Tattersall MH et al. Randomized clinical trials in oncology: Understanding and attitudes predict willingness to participate. J Clin Oncol 2001;19:3554-3561.
25. Adams-Campbell LL, Ahaghotu C, Gaskins M et al. Enrollment of African Americans onto clinical treatment trials: Study design barriers. J Clin Oncol 2004;22:730-734.
26. Lara PN Jr., Higdon R, Lim N et al. Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 2001;19:1728-1733.
27. Chen MS, Lara PN, Dang JH et al. Twenty years post-NIH Revitalization Act: Enhancing minority participation in clinical trials (EMPaCT): Laying the groundwork for improving minority clinical trial accrual: Renewing the case for enhancing minority participation in cancer clinical trials. Cancer 2014; 120(suppl 7):1091-1096.
28. Hawk ET, Habermann EB, Ford JG et al. Five National Cancer Institute-designated cancer centers’ data collection on racial/ethnic minority participation in therapeutic trials: A current view and opportunities for improvement. Cancer 2014; 120(suppl 7):1113-1121.
29. U.S. Census Bureau. State and county quick-facts. 2013. Available at http://quickfacts.census.gov/qfd/states/48/48113.html. Accessed November 26, 2014.
30. 30. Yorio JT, Yan J, Xie Y et al. Socioeconomic disparities in lung cancer treatment and outcomes persist within a single academic medical center. Clin Lung Cancer 2012;13:448-457.
31. 31. Javid SH, Unger JM, Gralow JR et al. A prospective analysis of the influence of older age on physician and patient decision-making when considering enrollment in breast cancer clinical trials (SWOG S0316). The Oncologist 2012;17: 1180-1190.
32. Van Spall HG, Toren A, Kiss A et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: A systematic sampling review. JAMA 2007;297:1233-1240.
33. Baggstrom MQ, Waqar SN, Sezhiyan AK et al. Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol 2011;6: 98-102.
34. Laaksonen M, Rahkonen O, Karvonen S et al. Socioeconomic status and smoking: Analysing inequalities with multiple indicators. Eur J Public Health 2005;15:262-269.
35. Hardy D, Liu CC, Xia R et al. Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer 2009;115:2199-2211.
36. Ledford H.Translational research: 4waystofix the clinical trial. Nature 2011;477:526-528.
37. Grover A, Slavin PL, Willson P.The economics of academic medical centers. N Engl J Med 2014;370: 2360-2362.
38. Berger O, Grønberg BH, Sand K et al.The length of consent documents in oncological trials is doubled in twenty years. Ann Oncol 2009;20: 379-385.